Protalix Biotherapeutics, Inc. (de) · AMEX:PLX
Protalix Biotherapeutics, Inc. (de) — Investor Presentation (May 2026)
23 slides from Protalix Biotherapeutics, Inc. (de)'s investor presentation, May 21, 2026
Slide 1: Protalix BioTherapeutics Corporate Presentation May 2026
1 PROTALIX BIOTHERAPEUTICS C O R P O R A T E P R E S E N T A T I O N J u n e 2024 PROTALIX BIOTHERAPEUTICS Pioneering solutions to transform the treatment of rare diseases C O R P O R A T E P R E S E N T A T I O N M a y 2026
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Exchange Act. Forward-looking statements are neither hist
Slide 3: Experienced leadership team
3 Experienced leadership team ORI KALID, PH.D. VP of R&D Dr. Kalid brings >20 years of leadership experience in pharmaceutical R&D. Previously he was co-founder and CEO of Silverskate Bio, as well as co-founder and CEO of Pi Therapeutics. He also served at Hotaru Innovation Partners, PREDIX/EPIX Pha
Slide 4: Accomplished Board of Directors
4 Accomplished Board of Directors AMOS BAR SHALEV Director POL F. BOUDES, M.D. Director GWEN A. MELINCOFF Director AHARON SCHWARTZ, PH.D. Director ELIOT FORSTER, PH.D. Chairman DROR BASHAN President & CEO, Director SHMUEL “MULI” BEN ZVI, PH.D. Director Christian Else Director BATM logo
Slide 5: Regulatory milestone payment of $25 million received from Chiesi; E4W dosing approved
5 Regulatory milestone payment of $25 million received from Chiesi EC and MHRA approve E4W dosing for Elfabrio® for adults with Fabry disease1 Now the only ERT in the EU and UK offering an every-4-weeks (E4W) option, reducing treatment burden from standard bi-weekly regimens 5 E4W dosing clinically
Slide 6: Protalix delivers innovations from concept to market
6 Protalix delivers innovations from concept to market Proven execution of delivering protein products for rare diseases with a pipeline for the future 1: Elfabrio has been approved for marketing in the United States, the European Union, and additional markets. Chiesi Global Rare Diseases, a busines
Slide 7: Two commercial products and a growing pipeline for the future
7 Indication Discovery and Preclinical Phase 1 Phase 2 Phase 3 Marketing Application Status Fabry Disease Approved in the US, European Union, and in additional other markets Gaucher Disease Approved in the US and other markets PEGylated Uricase (PRX-115) Uncontrolled Gout Phase 2 PRX-115 trial activ
Slide 8: Well-capitalized to advance Protalix to the next phase
8 Well-capitalized to advance Protalix to the next phase 8 $33.8M in revenue, which includes the $25M milestone (Q1 2026) $51.1M (as of: March 31, 2026); no debt no warrants ~80.5M shares of common stock outstanding (May 1, 2026) PRX-115 recombinant PEGylated uricase product candidate. Best-in-class
Slide 9: Key upcoming milestones and catalysts
9 Key upcoming milestones and catalysts Business development activities in rare renal diseases 3 revenue streams and projected consistent growth in the medium-term Significant milestone payments expected in mid- and long-term Continued internal R&D pipeline growth Elfabrio® Topline results from Ph2
Slide 10: PRX-115 in development for uncontrolled gout
10 Phase 2 Actively enrolling PRX-115 in development for uncontrolled gout
Slide 11: Gout and uncontrolled gout
11 Gout and uncontrolled gout • Metabolic disorder characterized by elevated blood urate that causes recurrent inflammatory arthritis and joint damage • Rheumatologists report that ~25% of their patients have above target urate blood levels which can lead to uncontrolled gout* • Uncontrolled gout is
Slide 12: The US Gout Market
12 11.3M1 5M2 1.2M2 0.3M3 0.18M3 6-8K4 The US Gout Market 1. Global Data – Aug 2025; 2. ACR Open Rheumatology Vol. 2 March 2020; 3. proprietary PRX Mkt Research 75 Rheums; 4. Internal estimates proprietary calculation ** Urate transporter 1 inhibitor; none currently available in the US † Neither the
Slide 13: PRX-115 Phase 1 single ascending dose study
13 PRX-115 Phase 1 single ascending dose study: encouraging data supports Phase 2 Recombinant PEGylated uricase enzyme produced via ProCellEx® 13 Study Scheme Primary Endpoint: Safety and tolerability Secondary Endpoints: PK, PD (uric acid levels) Subjects with elevated uric acid N = 8 per cohort (6
Slide 14: PRX-115 best in class potential for uncontrolled gout
14 PRX-115 best in class potential for uncontrolled gout Addresses an important unmet medical need 14 Phase 2 RELEASE study • Actively enrolling (NCT07280156) • Trial in uncontrolled gout patients • Fixed 36 mg dose across extended dosing intervals with and without methotrexate (MTX) • Top-line resu
Slide 15: PRX-115 Phase 2 double blind placebo-controlled study design
15 PRX-115 Phase 2 double blind placebo-controlled study design: actively enrolling MTX = Methotrexate Patient Population: uncontrolled gout Primary Endpoint: proportion of patients who achieve a reduction in serum uric acid (sUA) to <6.0 mg/dL for at least 80% of the time during Month 6 Secondary E
Slide 16: Commercial products
16 Commercial products Reliably partnered and delivering revenue
Slide 17: Two commercial products sustaining future growth
17 Rare autosomal recessive disorder (~1/40,000 WW) with systemic visceral and skeletal disease-causing disability and organ dysfunction Rare X-linked disorder (~1/40,000-60,000 males WW) with progressive renal, cardiac, and neurological burden Fabry disease Two commercial products sustaining future
Slide 18: Fabry disease competitive landscape
18 Fabry disease competitive landscape ~$2.2B market (2025) expected to reach over ~$3.2B (2031), CAGR of 6.4%1 18 Product Name Fabrazyme® Replagal® Galafold® Elfabrio® Parent Company Mechanism ERT ERT Pharmacological chaperone ERT longer half-life (pegylated) Approved for Adults & pediatric patient
Slide 19: Commitment and execution from global partnership with Chiesi
19 Commitment and execution from global partnership with Chiesi Committed Global Partner 1 • International research-focused biopharmaceutical group with sales of €3.6B in 2025 (reflecting 8% growth year-on-year) • Air (respiratory) - €1.9B, Rare - €906M (22.3% growth), Care (Specialty) - €904M • The
Slide 20: Growth strategy
20 Growth strategy Next phase of the company
Slide 21: Research strategy - leveraging internal strengths
21 Research strategy - leveraging internal strengths to fuel the company's next phase Proven ability to drive discovery, development, and registration of new drugs 21 Internal development Protein therapeutics Plant cell-based expression Chemical modification PEGylation, other Drug delivery Exploring
Slide 22: Protalix delivers innovation from concept to the market
22 Protalix delivers innovation from concept to the market * (as of May 1, 2026) Revenues USD 33.8M for Q1 2026 Cash and Shares Outstanding USD 51.1M (March 31, 2026) 80.5M shares of common stock* Debt No Debt / Warrants Growing pipeline for the company's next phase • PRX-115 best-in-class potential
Slide 23: Protalix BioTherapeutics Corporate Presentation
23 PROTALIX BIOTHERAPEUTICS C O R P O R A T E P R E S E N T A T I O N J u n e 2024 PROTALIX BIOTHERAPEUTICS Pioneering solutions to transform the treatment of rare diseases C O R P O R A T E P R E S E N T A T I O N M a y 2026
Protalix BioTherapeutics — Investor Presentation (May 2026) on 6ix